key: cord-0308870-jlpex6r4
authors: Winata, I. G. S.; Simatupang, J.; Polim, A. A.; Togar, Y.; Tondang, A. E.
title: The outcome of Gynecologic Cancer Patients With The Covid-19 Infection: A Systematic Review And Meta-Analysis
date: 2022-03-21
journal: nan
DOI: 10.1101/2022.03.20.22272676
sha: 55392a46d4689a9ff15267803b5fac20f5d2fda6
doc_id: 308870
cord_uid: jlpex6r4

Objective: Cancer is comorbidity, which can lead to progressive worsening of Covid-19 with increased mortality. This is a systematic review and meta-analysis to get evidence of adverse outcomes of Covid-19 in gynecologic cancer. Methods: Searches through PubMed, Google Scholar, ScienceDirect, and medRxiv to find articles on the outcome of gynecologic cancer with Covid-19 (24 July 2021-19 February 2022). Newcastle-Ottawa Scale tool used to evaluate the quality of included studies. Pooled odds ratio (OR), 95% confidence interval (CI), random-effects model were presented. This study registered to PROSPERO (CRD42021256557). Results: We accepted 49 studies with (1994 gynecologic cancer with Covid-19). Covid-19 infection was lower in gynecologic cancer vs hematologic cancer (OR 0.71, CI 0.56-0.89, p 0.003). Severe Covid and death were lower in gynecologic cancer vs lung and hematologic cancer (OR 0.36, CI 0.16-0.80, p 0.01), (OR 0.26, CI 0.10-0.67 p 0.005), (OR 0.52, CI 0.43-0.63, p <0.0001), (OR 0.65, CI 0.49-0.87, p 0.003) respectively. Increased Covid death is seen in gynecologic cancer vs breast, non-covid cancer, and non cancer covid (OR 1.51, CI 1.20-1.90, p 0.0004), (OR 12.21, CI 8.39- 17.77, p <0.0001), (OR 3.06, CI 2.32-4.04, p <0.0001) respectively. Conclusion: Gynecologic cancer had increased Covid-19 adverse outcomes compared to non-cancer, breast cancer, non-metastatic, and Covid-19 negative population. Gynecologic cancer had lowered Covid-19 adverse outcomes compared to other cancer types, lung cancer, and hematologic cancer. Lack of age and comorbidities stratification due to limited data were limitations. These findings may aid health policies and services during the ongoing global pandemic.

This is a systematic review and meta analysis study that presents pooled evidence of outcome among Analysis from SARS-Cov-2 infection shows lower infection with gynecologic cancer patients vs hematologic cancer cohort (OR 0.71, CI 0.56-0.89, p 0.003). We hope the result of this meta analysis will be useful to providers practicing in cancer centers and tertiary cancer referral hospitals thus better practices and care services given to gynecologic cancer patients infected with / without the Covid-19 during the ongoing global pandemic can be achieved.

To our knowledge this is the first systematic review and meta analysis which emphasizes on reporting the outcome of gynecologic cancer patients with the Covid-19 infection. We also found no publication bias across 49 studies we have gathered and used as meta analysis data.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted  https://doi.org/10.1101/2022.03.20.22272676 doi: medRxiv preprint

The Covid-19 pandemic has changed the way of health care providers around the world to manage care provided to their patients. The pandemic has also proven to shift the attitude of standard practice and procedure between providers and patients, for example, to reduce gynecologic cancer patients visiting the hospital as possible because the risk of getting infected with Covid-19 is increased regarding their comorbidities. 1 8 The world has been experiencing wave of active case surges by these variants and on 26 November 2021 the WHO designated the variant Omicron (B.1.1.529) as an addition to the list. 9 Thus we attempt to review the literature and quantify the effect of the SARS-Cov-2/Covid-19 infection among gynecologic cancer patients whether the risk of infection, hospitalization, severity, and mortality are increased than non-gynecologic cancer population.

We conducted this systematic review and meta-analysis according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses/PRISMA statement. 10 This study and its protocol were registered to PROSPERO (CRD42021256557).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Pubmed/Medline search with ("COVID-19" or "2019-nCoV" or "SARS-CoV" or SARSCOV2 or 2019-nCov or "2019 coronavirus" or covid19) AND (gynecology or gynaecology) AND (tumor or malignancy or cancer) AND (outcomes or outcome) AND (gyn* tum* or gyn *malign* or gyn* cancer) AND (cancer surgery or oncolog* surger*) AND (brachytherapy or radiotherapy). We used "Gynecologic cancer AND Covid-19" with Google Scholar, Science Direct, and medRxiv. Two authors ( YT & AET ) separately handled the literature search.

Findings were accumulated and stored in Mendeley and Zotero for management and automated duplicate identification. Thorough stepwise screening from title and abstract was then conducted to determine possible article inclusion. Potentially eligible studies were then evaluated for in-depth full-text review. Each author would consult senior authors ( JS, AAP, & IGSW) to resolve any differences found during the literature's selection process.

Two authors ( YT & AET ) extracted data independently and stored them in The Microsoft Excel spreadsheet.

Data then discussed for an agreement. Name of authors, year of publication, country, type of studies, study period, number of patients, comparators, and target conditions were collected. The NOS / Newcastle-Ottawa Scale will be used by authors to assess the quality of cohort and case-control study, and The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for an analytical cross-sectional study. 11 Two authors ( YT & AET ) performed the assessment and results were discussed with the first author ( IGSW ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 21, 2022. ; https://doi.org/10.1101/2022.03.20.22272676 doi: medRxiv preprint

The main outcome of interest were Covid-19 mortality and severity. Covid-19 severity is defined as either ICU admission, ARDS, or need for mechanical ventilation. Covid-19 infection and hospitalization were decided as secondary outcomes.

We performed data analysis mainly using Review Manager 5.4.1 ( RevMan 5.4.1) by Cochrane collaboration. 12 Additional synthesis if any were needed then performed with STATA-16. We synthesized the dichotomous outcome from each study with an odds ratio (OR). The random-effects model (DerSimonian and Laird) was used to present pooled OR with 95% CI (Confidence Interval) and the result of overall effect (p). We addressed the presence of heterogeneity with I 2 as 0% to 40%: might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity. 13 We performed subgroup analysis by cancer type, presence of metastatic disease, and cancer treatment. Sensitivity analysis would be performed by dividing multi-center/single-center studies and removing/including the latest study period if concerns were raised of patients population duplication thus we could present robust pooled evidence. 14

A total of 49 studies involving the Covid-19 positive population, among them are 1994 gynecologic cancer patients, 220967 non-cancer patients, and 28658 other cancer type patients. 4080990 cancer patients were found to be Covid-19 free. Study selection and summary of included studies were presented in Figure 1 and Table 1 respectively. The risk of bias of each study was shown in Fig. S1 

Covid-19 infection was equivalent between gynecologic cancer and other cancer gathered from 8 studies (OR 1.02, CI 0.85-1.24, p 0.80, I 2 62%) Fig. S7 . 33, 39, 49, 50, 54, 55 Gynecologic cancer had fewer Covid-19 associated death compared to other cancer according to 27 studies (OR 0.84, CI 0.72-0.97, p 0.02, I 2 4%) Figure 2 . [18] [19] [20] [24] [25] [26] [27] [28] 30, 32, 37, [39] [40] [41] [42] 45, 47, 49, [51] [52] [53] [54] 56, 57, 59 Covid-19 associated severity was not statistically significant from 6 studies between gynecologic cancer and other cancer (OR 0.56, CI 0.30-1.03, p 0.06, I 2 0%) Fig. S8 . 24, 25, 32, 52, 53, 59 Lastly, data from 2 studies showed non statistical significance from Covid-19 hospitalization in gynecologic cancer patients than other cancer (OR 0.73, CI 0.50-1.06, p 0.10, I 2 82%) Fig. S9 . 30, 49 

Covid-19 infection among gynecologic cancer and non cancer population was comparable from 5 studies (OR 1.06, CI 0.70-1.62, p 0.78, I 2 53%) Fig. S10 . 35, 39, 49, 58 Data from 10 studies revealed death from Covid-19 was higher in gynecologic cancer than non cancer patients (OR 3.06, CI 2.32-4.04, p <0.0001, I 2 28%) Figure   3 . 18, 20, 24, 27, 38, 39, 42, 49, 53 Lastly, severe Covid-19 was not statistically significant in gynecologic cancer than non cancer patients from 2 studies (OR 1.85, CI 0.77-4.44, p 0.17, I 2 0%) Fig. S11 . 24 Figure 4 . 16, 39, 44, 49 

Data from 9 studies showed among whose receiving cancer treatment, Covid-19 infection was not statistically significant in gynecologic cancer patients compared to other cancer (OR 0.74, CI 0.54-1.02, p 0.06, I 2 0%) Fig.   S12 . 15 Fig. S14 . 25, 32, 44, 46, 59 According to 4 studies, gynecologic cancer with cancer treatment compared to whose not receiving cancer treatment, Covid-19 death was equivalent between the two (OR 1.06, CI 0.56-2.01, p 0.85, I 2 0%) Fig. S15 . 22, 25, 32, 36 Lastly from 4 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 21, 2022. ; https://doi.org/10.1101/2022.03.20.22272676 doi: medRxiv preprint studies available, severity from Covid-19 was not statistically significant in gynecologic cancer who had cancer treatment than who had none (OR 0.36, CI 0.09-1.42, p 0.14, I 2 44%) Fig. S16 . 25, 32, 36, 59 

3 studies provided data on metastatic status. 20, 25, 39 Gynecologic cancer with metastasis was having increased Covid-19 death than those with localized cancer (OR 1.53, CI 1.06-2.21, p 0.02, I 2 0%) Figure 5 . Contrary, among metastatic diseases, death was not statistically significant between gynecologic cancer compared to other cancer (OR 0.77, CI 0.54-1.11, p 0.17, I 2 0%) Fig. S17 .

13 studies provided data on Covid-19 infectivity, infection was not statistically significant in gynecologic cancer than lung cancer (OR 0.85, CI 0.61-1.18, p 0.33, I 2 73%) Fig. S18 . 15, 17, 23, 29, 33, 39, 43, 49, 50, 55, 60 Data from 28 studies revealed that gynecologic cancer had fewer Covid-19 death than lung cancer patients (OR 0.52, CI 0.43-.063, p <0.0001, I 2 4%) Figure 6A . 15, [18] [19] [20] [21] [24] [25] [26] [27] [28] 30, 32, 37, 39, [40] [41] [42] 45, [47] [48] [49] [51] [52] [53] 56, 57 Data from 6 studies showed that gynecologic cancer was having less severity from Covid-19 than lung cancer (OR 0.36, CI 0.16-0.80, p 0.01, I 2 0%) Figure   6B . 24, 25, 32, 52, 53, 59 Lastly, 2 studies reported fewer hospitalization associated with Covid-19 in gynecologic cancer than lung cancer (OR 0.54, CI 0.40-0.73, p <0.0001, I 2 0%) Figure 6C . 17,30

Data from 13 studies showed gynecologic cancer and breast cancer were equivalent on having Covid-19 infection (OR 1.07, CI 0.94-1.22, p 0.30, I 2 18%) Fig. S19 . 15, 17, 29, 33, 39, 43, 46, 49, 50, 55, 60 Interestingly from 24 studies, gynecologic cancer was experiencing higher Covid-19 death compared to breast cancer patients (OR 1.51, CI 1.20-1.90, p 0.0004, I 2 21%) Figure 7A . 15, [18] [19] [20] [25] [26] [27] [28] 30, 32, 37, [39] [40] [41] [42] 45, [47] [48] [49] 52, 53, 56, 57 Covid-19 severity was not statistically significant from 7 studies between gynecologic cancer and breast cancer (OR 0.83, CI 0.40-1.72, p 0.62, I 2 0%) Fig. S20 . 24, 25, 32, 46, 52, 53, 59 Lastly, data from 2 studies showed gynecologic cancer was experiencing higher hospitalization from Covid-19 compared to breast cancer (OR 1.52, CI 1.18-1.96, p 0.001, I 2 0%) Figure   7B . 17,30

Data available from 8 studies revealed gynecologic cancer was having less infection of Covid-19 compared to hematologic cancer patients (OR 0.71, CI 0.56-0.89, p 0.0003, I 2 67%) Figure 8A . 15, 33, 39, 49, 50, 55 Data also showed that gynecologic cancer was experiencing fewer Covid-19 death compared to hematologic cancer from 22 studies (OR 0.65, CI 0.49-0.87, p 0.003, I 2 45%) Figure 8B . 15, 19, 20, [24] [25] [26] [27] [28] 30, 32, 37, 39, 40, 42, [47] [48] [49] 51, 53, 57 Lastly, 4 studies also showed that gynecologic cancer was having less severity from Covid-19 compared to hematologic cancer . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 21, 2022. ; https://doi.org/10.1101/2022.03.20.22272676 doi: medRxiv preprint (OR 0.26, CI 0.10-0.67, p 0.005, I 2 0%) Figure 8C . 24, 25, 32, 53 Gender Age

We performed sensitivity analysis by reproducing each outcome synthesis to pre-specified single center to multicenter studies, furthermore excluding overlapped study periods associated with its study centers thus only one center with the most recent study period was included Table S1 . After the exclusion, 4 studies showed the nonstatistical significance of severe Covid-19 among those receiving cancer treatment in gynecologic cancer than other cancer patients (22 gynecologic cancer, 256 other cancer, OR 1.18, CI 0.19-7.49, p 0.86, I 2 36%). 25, 32, 44, 46 After the exclusion, 4 studies showed severe Covid-19 between gynecologic cancer and breast cancer was comparable (49 gynecologic cancer, 134 breast cancer, OR 0.95, CI 0.29-3.15, p 0.93, I 2 21%). 25, 32, 46, 52 Aside from these, the remainder of calculated OR from reproducing each outcome synthesis by exclusion were within good accordance.

We found no publication bias within our included studies though at first, we identified an asymmetrical funnel plot; it was caused solely by heterogeneity nonetheless (Fig. S21-24) . After subgroup identification, the funnel plow was corrected and the calculated Egger & Begg's test for overall Covid death, severity, and hospitalization were p 0.1701, p 1.5674 respectively. For data associated with Covid-19 infection, the values were p 0.2109, p 1.7157 respectively.

We believe this is the first comprehensive meta-analysis done regarding the outcome of Covid-19 to the gynecologic cancer population. With the 1994 Covid-19 positive gynecologic cancer that we amassed, we hope we provide new insight into how the global pandemic is affecting practice and service affecting gynecologic cancer. Several meta-analyses showed the prevalence for cancer with Covid-19 infection were 2-4%, Covid-19 mortality also higher in the cancer patients cohort. [5] [6] [7] [61] [62] [63] [64] [65] In this meta-analysis gynecologic cancer patients is at increased risk of Covid-19 death compared to the non-cancer population (OR 3.06, CI 2.32-4.04, p <0.0001, I 2 28%), most studies also support this finding by providing evidence of greater Covid-19 adverse outcome in cancer patients. [5] [6] [7] [61] [62] [63] [64] [65] Contrary to the "N3C" multicenter study from the United States, our result present a . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted 28%). 66 Our finding shows gynecologic cancer with metastatic disease has an increased Covid-19 death compared to whose cancer are localized (OR 1.53, CI 1.06-2.21, p 0.02, I 2 0%), most studies also report identical outcomes to ours. 65, 67, 68 Our analysis also shows gynecologic cancer is associated with higher Covid-19 death and hospitalization compared to breast cancer patients (OR 1.51, CI 1.20-1.90, p 0.0004, I 2 21%), (OR 1.52, CI 1.18-1.96, p 0.001, I 2 0%) respectively. Other meta-analyses, as well as studies done by "CCC19" and the "N3C" also supported this finding. 62 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Lastly, data from the United Kingdom, Turkey, and Italy show that while maintaining gynecologic cancer treatment during the pandemic time the Covid-19 infection rate is found at a low level, 1/289 is Covid-19 positive and 1 post-operative death suspected of Covid-19 (UK), 2/200 is suspected with Covid-19 but neither was positive for COVID-19 on polymerase chain reaction testing (Turkey), and 1/930 is Covid-19 positive (Italy). [75] [76] [77] We hope these findings will be useful among gynecologist-oncologists in cancer centers or tertiary cancer referral centers who provide care to gynecologic cancer patients during the ongoing Covid-19 pandemic.

Limitations from our analysis are, we cannot perform specific gynecologic cancer type, age, and associated comorbidities due to limited data.

None declared.

The report which of the following are publicly available and they can be found at the supplementary material. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 21, 2022. ; https://doi.org/10.1101/2022.03.20.22272676 doi: medRxiv preprint

COVID-19 Global Pandemic: Options for Management Gynecologic Cancers

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Coronavirus Concerns: What do women with gynecologic cancer need to know during The Covid-19 crisis

Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis

The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis

Effect of Cancer on Clinical Outcomes of Patients With Covid-19

Analysis of Patient Data

SARS-CoV-2 Variants of Concern

Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions forMember States

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?

Chapter 10: Analysing data and undertaking meta-analyses

Available from . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Editorial Concern-Possible Reporting of the Same Patients With COVID-19 in Different Reports

Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer

Perioperative SARS-CoV-2 infection among women undergoing major gynecologic cancer surgery in the COVID-19 era: A nationwide

Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?

Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience

Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients

Comparison of Cancer Patients to Non-Cancer Patients among COVID-19 Inpatients at a National Level. Cancers (Basel)

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

Cancer patients affected by COVID-19: Experience from Milan

Prevalence of COVID-19 Infection in Asymptomatic Cancer Patients in a District With High Prevalence of SARS-CoV-2 in Italy

Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak

Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute

Systemic pro-inflammatory response identifies patients with cancer . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

Outcomes of COVID-19 Patients under Cytotoxic Cancer Chemotherapy in Brazil. Cancers (Basel)

Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

The Impact of COVID-19 on Brachytherapy During the Pandemic: A Rutgers-Robert Wood Johnson Barnabas Health Multisite Experience

Chemotherapy and COVID-19 Outcomes in Patients With Cancer

COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway

Is elective cancer surgery feasible during the lock-down period of the COVID-19 pandemic? Analysis of a single institutional experience of 404 consecutive patients

Is it safe to perform elective gynaecologic surgery during the two peaks of COVID-19 pandemic?

COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection

Comparison and impact of COVID-19 for patients with cancer: a survival analysis of fatality rate controlling for age, sex and cancer type

Clinical characteristics and risk factors for mortality in cancer patients with COVID-19

A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

A Statewide Multi-Institutional Study of Asymptomatic Pretreatment Testing of Radiation Therapy Patients for SARS-CoV-2 in a High-Incidence Region of the United States

Continuity of Cancer Care: The Surgical Experience of Two Large Cancer Hubs in London and Milan. Cancers (Basel)

COVID-19 and cancer: A comparative case series

Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19

Cancer and the risk of coronavirus disease 2019 diagnosis, hospitalisation and death: A population-based multistate cohort study including 4 618 377 adults in Catalonia, Spain

COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients

An online tool for predicting the prognosis of cancer patients with SARS-CoV-2 infection: a multi-center study

Association between recent oncologic treatment and mortality among patients with carcinoma who are hospitalized with COVID-19: A multicenter study

Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study

FDG PET/CT in oncologic patients with unsuspected asymptomatic infection with SARS-CoV-2

Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection

Clinical characteristics and outcomes of cancer patients with COVID-19

Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study

Clinical Characteristics of COVID-19 After Gynecologic Oncology Surgery in Three Women: A Retrospective Review of Medical Records

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients-First Results from the PAPESCO-19 Cohort Study

Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: A systematic review and meta-analysis

MD, A Systematic Review and Meta-Analysis of Cancer Patients Affected by a Novel Coronavirus

Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis

Clinical characteristics, outcomes, and risk factors for mortality in hospitalized patients with COVID-19 and cancer history: a propensity score-matched study

Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort Collaborative (N3C)

Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

COVID-19 in patients with lung cancer

ERAS protocols in gynecologic oncology during COVID-19 pandemic

Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology -A systematic review and meta-analysis

The impact of the COVID-19 coronavirus pandemic on the surgical management of gynecological cancers: Analysis of the multicenter database of the French SCGP and the FRANCOGYN group

Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals

Maintaining surgical care delivery during the COVID-19 pandemic: A comparative cohort study at a tertiary gynecological cancer centre

Performing gynecologic cancer surgery during the COVID-19 pandemic in Turkey: A multicenter retrospective obser

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 21, 2022. ; https://doi.org/10.1101/2022.03.20.22272676 doi: medRxiv preprint